Even as it’s moving into the US tobacco alternatives market, Philip Morris International (PMI) may be setting itself up for a future move into the cannabis industry. The company has reportedly purchased a patent for a genetically modified cannabis plant, and is said to have invested $20m in an Israeli company that makes cannabis inhalers.
Meanwhile, an expert on cannabis and behaviour has told CBD-Intel that reports of 60 people suffering medical ill-effects from vaping products marketed as containing cannabinoid oil suggested symptoms consistent with them having received “tainted product”.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.